GlassScriptPhysician profile
Caitlin V Collier
NPI 1013484211
$2,124.40
in general payments reported to CMS, 2019-2025
32 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $447 · 2023: $385 · 2024: $593 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.11 | 2021-2025 | |
| Corcept Therapeutics | $237.12 | 2022-2024 | Korlym |
| Gilead Sciences, INC. | $211.07 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.68 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $152.98 | 2022-2025 | Tavneos, Evenity, Prolia |
| Dexcom, INC. | $145.29 | 2024-2025 | Dexcom G6 Transmitter |
| Mallinckrodt Hospital Products INC. | $105.34 | 2023-2025 | Acthar |
| Merck Sharp & Dohme LLC | $80.35 | 2022-2025 | Zerbaxa |
| Supernus Pharmaceuticals, INC. | $60.29 | 2021-2022 | |
| Melinta Therapeutics, LLC | $45.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $44.22 | 2023 | |
| Lilly USA, LLC | $42.28 | 2024 | Mounjaro, Jardiance |
| Paratek Pharmaceuticals, INC. | $31.76 | 2021-2025 | Nuzyra |
| Baxter Healthcare | $30.63 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Ultragenyx Pharmaceutical INC. | $30.07 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.43 | 2024 | Hyqvia |
| Ani Pharmaceuticals, INC. | $29.01 | 2024 | Purified Cortrophin Gel |
| Ucb, INC. | $28.45 | 2023-2025 | Cimzia, Bimzelx |
| Novo Nordisk INC | $25.72 | 2025 | Ozempic |
| Biogen, INC. | $25.15 | 2022 | |
| Averitas Pharma INC. | $23.94 | 2023 | Qutenza |
| Sobi, INC | $22.29 | 2025 | |
| Boston Scientific Corporation | $19.63 | 2023 | Watchman Access System |
| Kyowa Kirin, INC. | $18.28 | 2024 | Crysvita |
| United Therapeutics Corporation | $17.94 | 2024 | Tyvaso |
| Sk Life Science, INC. | $16.96 | 2021 | |
| Glaxosmithkline, LLC. | $16.83 | 2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $16.08 | 2024 | |
| Daiichi Sankyo INC. | $14.87 | 2021 | |
| Shionogi INC | $14.31 | 2021 | |
| La Jolla Pharmaceutical Company | $14.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.